Historical salary details - Dr. Marc Tessier-Lavigne, PhD, Independent Director, Denali Therapeutics Inc
Dr. Marc Tessier-Lavigne, PhD is the Independent Director of Denali Therapeutics Inc.
Dr. Marc Tessier-Lavigne, Phd
Independent Director
$ 372.0 K
Gross Remuneration
-
Current Company
Denali Therapeutics Inc
| YEAR | COMPANY | POSITION | SALARY | INCREMENT |
|---|---|---|---|---|
| 2024 | Denali Therapeutics Inc | Independent Director | 372.0 K | -13.9 % |
| 2023 | Regeneron Pharmaceuticals, Inc. | Independent Director | 667.1 K | -4.7 % |
| 2023 | Denali Therapeutics Inc | Independent Director | 431.9 K | -6.4 % |
| 2022 | Regeneron Pharmaceuticals, Inc. | Independent Director | 700.0 K | -0.0 % |
| 2022 | Denali Therapeutics Inc | Independent Director | 461.3 K | 12.2 % |
| 2021 | Regeneron Pharmaceuticals, Inc. | Independent Director | 700.1 K | 0.0 % |
| 2021 | Denali Therapeutics Inc | Independent Director | 411.0 K | 1.8 % |
| 2020 | Regeneron Pharmaceuticals, Inc. | Independent Director | 700.0 K | 0.0 % |
| 2020 | Denali Therapeutics Inc | Independent Director | 403.8 K | -0.3 % |
| 2019 | Regeneron Pharmaceuticals, Inc. | Independent Director | 700.0 K | -42.1 % |
| 2019 | Denali Therapeutics Inc | Independent Director | 405.1 K | -0.0 % |
| 2018 | Regeneron Pharmaceuticals, Inc. | Independent Director | 1.2 M | -7.2 % |
| 2018 | Denali Therapeutics Inc | Independent Director | 405.1 K | -36.0 % |
| 2017 | Regeneron Pharmaceuticals, Inc. | Independent Director | 1.3 M | -37.7 % |
| 2017 | Denali Therapeutics Inc | Director | 632.9 K | 4119.3 % |
| 2016 | Regeneron Pharmaceuticals, Inc. | Independent Director | 2.1 M | 1.3 % |
| 2016 | Agios Pharmaceuticals Inc | - | 302.8 K | -75.6 % |
| 2016 | Denali Therapeutics Inc | Director | 15 K | - |
| 2016 | Agios Pharmaceuticals Inc | Chairman of the Board | - | - |
| 2015 | Regeneron Pharmaceuticals, Inc. | Independent Director | 2.1 M | 16.9 % |
| 2015 | Agios Pharmaceuticals Inc | Chairman of the Board | 1.2 M | 230.6 % |
| 2015 | Pfizer Inc. | - | 214.1 K | -28.6 % |
| 2015 | Pfizer Inc. | Independent Director | - | - |
| 2014 | Regeneron Pharmaceuticals, Inc. | Independent Director | 1.8 M | 24.3 % |
| 2014 | Agios Pharmaceuticals Inc | Independent Director | 374.9 K | 111.3 % |
| 2014 | Pfizer Inc. | Independent Director | 300 K | 9.1 % |
| 2013 | Regeneron Pharmaceuticals, Inc. | Independent Director | 1.4 M | 175.3 % |
| 2013 | Pfizer Inc. | Independent Director | 275 K | -0.7 % |
| 2013 | Agios Pharmaceuticals Inc | Independent Director | 177.4 K | 332.1 % |
| 2012 | Regeneron Pharmaceuticals, Inc. | Independent Director | 515.4 K | -22.0 % |
| 2012 | Pfizer Inc. | Independent Director | 277 K | 91.1 % |
| 2012 | Agios Pharmaceuticals Inc | Independent Director | 41.1 K | - |
| 2011 | Regeneron Pharmaceuticals, Inc. | Independent Director | 661.1 K | - |
| 2011 | Pfizer Inc. | Independent Director | 145.0 K | - |